SAN DIEGO AND TORONTO, Dec. 3,
2014 /PRNewswire/ - Aptose Biosciences Inc. (Aptose)
(NASDAQ: APTO; TSX: APS), a clinical-stage company developing
targeted agents and molecular diagnostics to treat the underlying
mechanisms of cancer, today announced that preclinical data for its
lead investigational anticancer therapeutic APTO-253 will be
presented at the 56th American Society of Hematology (ASH) Annual
Meeting and Exposition in San
Francisco, December 6-9,
2014.
At the 2014 ASH meeting, Aptose will present preclinical in vivo
data on APTO-253 including studies evaluating activity as a single
agent and in combination with azacitidine in murine xenograft AML
models. The accepted abstract is available online on the ASH
conference website:
https://ash.confex.com/ash/2014/webprogram/Paper73402.html
Poster Presentation Details
Title: APTO -253 Induces KLF4 to Promote Potent in Vitro
Pro-Apoptotic Activity in Hematologic Cancer Cell Lines and
Antitumor Efficacy as a Single Agent and in Combination with
Azacitidine in Animal Models of Acute Myelogenous Leukemia.
- Monday, December 8, 2014,
6:00 PM - 8:00 PM PT
- Location: West Building, Level 1 (Moscone Center)
- Paper # 4813
- Session: 802. Chemical Biology and Experimental Therapeutics:
Poster III
APTO-253 is a clinical-stage small molecule therapeutic that
acts through induction of the innate tumor suppressor gene
Krüppel-like factor 4 (KLF4), and suppression of KLF4 gene
expression has been reported as a key driver in the leukemogenesis
of AML and subsets of other hematologic diseases. Earlier
this year, Aptose researchers reported the ability of APTO-253 to
induce cell death, or apoptosis, in multiple blood cancer cell
lines including AML, as well as in vitro synergy with various
classes of conventional approved therapies for AML or
myelodysplastic syndromes (MDS).
In a prior single-agent, Phase 1 clinical study, APTO-253
demonstrated antitumor activity and a robust safety profile in
patients with solid tumors.
APTO-253 is currently being evaluated in an ongoing open-label,
single-agent, dose-escalating Phase 1b clinical trial in patients
with relapsed or refractory hematologic malignancies, including AML
and high-risk MDS.
About Aptose
Aptose Biosciences is a clinical-stage biotechnology company
committed to discovering and developing personalized therapies
addressing unmet medical needs in oncology. Aptose is advancing new
therapeutics focused on novel cellular targets on the leading edge
of cancer research coupled with companion diagnostics to identify
the optimal patient population for our products. The company's
small molecule cancer therapeutics pipeline includes products
designed to provide additive or synergistic efficacy with existing
anti-cancer therapies and regimens without overlapping toxicities.
For further information, please visit
www.aptosebiosciences.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of Canadian and U.S. securities laws. Such statements
include, but are not limited to, statements relating to Aptose's
plans, objectives, expectations and intentions and other statements
including words such as "continue", "expect", "intend", "will",
"should", "would", "may", and other similar expressions. Such
statements reflect our current views with respect to future events
and are subject to risks and uncertainties and are necessarily
based upon a number of estimates and assumptions that, while
considered reasonable by us are inherently subject to significant
business, economic, competitive, political and social uncertainties
and contingencies. Many factors could cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements described in this press
release. Such expressed or implied factors include, among others:
changes in our stock price; our ability to meet listing
requirements; our ability to obtain the capital required for
research and operations; the inherent risks in early stage drug
development including demonstrating efficacy; development time/cost
and the regulatory approval process; the progress of our clinical
trials; our ability to find and enter into agreements with
potential partners; our ability to attract and retain key
personnel; changing market conditions; stock market volatility; and
other risks detailed from time-to-time in our ongoing quarterly
filings, annual information forms, annual reports and annual
filings with Canadian securities regulators and the United States
Securities and Exchange Commission.
Should one or more of these risks or uncertainties materialize,
or should the assumptions set out in the section entitled "Risk
Factors" in our filings with Canadian securities regulators and the
United States Securities and Exchange Commission underlying those
forward-looking statements prove incorrect, actual results may vary
materially from those described herein. These forward-looking
statements are made as of the date of this press release and we do
not intend, and do not assume any obligation, to update these
forward-looking statements, except as required by law. We cannot
assure you that such statements will prove to be accurate as actual
results and future events could differ materially from those
anticipated in such statements. Investors are cautioned that
forward-looking statements are not guarantees of future performance
and accordingly investors are cautioned not to put undue reliance
on forward-looking statements due to the inherent uncertainty
therein.
SOURCE Aptose Biosciences Inc.
PDF available at:
http://stream1.newswire.ca/media/2014/12/03/20141203_C9024_DOC_EN_43277.pdf